ArticleBMJ neurology open2025
Subgroup analysis of tumefactive demyelinating lesions: clinical, imaging features and outcomes.
Article in BMJ neurology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumefactive demyelinating lesions (TDLs) are rare, large demyelinating lesions of the central nervous system that can mimic brain tumours in radiological appearance. They have been observed across multiple demyelinating diseases. Previous studies have suggested that antibody profiles may correlate with distinct clinical or imaging characteristics, but detailed comparisons between antibody-defined subgroups in TDLs remain limited. Methods: We retrospectively analysed 30 patients with confirmed TDLs. Demographic, clinical, imaging and laboratory data were collected, and patients were stratified by myelin oligodendrocyte glycoprotein (MOG) and N-methyl-D-aspartic acid receptor (NMDAR) antibody results. Lesion characteristics were evaluated on brain MRI, and outcomes were assessed by modified Rankin Scale at last follow-up. Statistical comparisons were made between antibody-positive and antibody-negative subgroups. Results: Among TDLs subgroups, MOG+ patients had elevated cerebrospinal fluid white cell counts and showed greater lesion volume reduction on follow-up MRI than MOG- patients. NMDAR+ patients showed elevated levels of systemic inflammatory markers compared with NMDAR- counterparts. Regardless of antibody status, most TDLs patients responded well to immunotherapy, with 86.7% achieving a favourable outcome. Conclusions: TDLs represent a heterogeneous inflammatory syndrome. MOG and NMDAR antibodies influence the clinical and laboratory characteristics of TDL patients but have limited impact on prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.